Investigator Clinical Trial Experience
Investigator Network Experience

“RMP investigators consistently deliver accelerated enrollment and predictable study execution across multi-site programs.”

The investigators within the Research Management Partners (RMP) network represent a highly experienced group of physicians actively engaged in clinical research across multiple therapeutic areas. Serving as Principal Investigators and Sub-Investigators, they have collectively contributed to 150+ industry-sponsored clinical trials spanning Phase I through Phase IV, including interventional, observational, device-based, and real-world evidence programs.

Operating within active clinical practices across Florida and Puerto Rico, our investigators provide direct access to large, diverse, and treatment-experienced patient populations. This embedded model enables accelerated enrollment, improved retention, and more accurate feasibility assessments—key drivers of successful study execution.

RMP investigators have extensive experience across:
• psychiatry
• pulmonology
• gastroenterology
• cardiology
• endocrinology
• rheumatology
• infectious diseases
• neurology
• dermatology
• nephrology
• metabolic disorders
• oncology and hematology
• immunology and inflammatory diseases

Expanded Oncology, Laboratory & Imaging Integration

RMP has further strengthened its network through the integration of:

• board-certified hematology/oncology investigators actively engaged in clinical research and patient care

• a network of 10 CLIA-certified laboratories across Florida supporting advanced biospecimen processing and biomarker-driven programs

• access to dedicated imaging centers enabling protocol-driven imaging, disease monitoring, and longitudinal assessment

This integrated infrastructure allows RMP to support oncology and precision medicine studies requiring coordinated execution across clinical care, laboratory workflows, imaging endpoints, and translational research activities.

By aligning investigators with laboratory and imaging capabilities, RMP ensures:
• seamless execution of biomarker-driven and translational protocols
• high-quality sample collection linked to clinical and imaging data
• reduced operational fragmentation across vendors
• end-to-end oversight of complex study designs

Dermatology & Immunology Research Expansion

RMP has further expanded its dermatology and immunology clinical research infrastructure through the integration of board-certified dermatology investigators and affiliated dermatology research operations across Southeast Florida.

This expansion includes extensive experience in:
• psoriasis
• atopic dermatitis
• hidradenitis suppurativa
• inflammatory skin diseases
• biologic therapies
• dermatologic immunology
• chronic dermatologic conditions
• observational and interventional dermatology studies

The integration of Dr. Jillian H. Frieder, MD, FAAD, and affiliated dermatology research operations significantly strengthens RMP’s ability to support dermatology-focused sponsors and CROs requiring experienced investigators, biologic/immunology expertise, and access to diverse patient populations.

Dr. Frieder brings extensive Phase II–IV clinical trial experience across multiple industry-sponsored dermatology programs involving sponsors such as:
• Sanofi
• UCB
• Eli Lilly
• Novartis
• Regeneron
• Boehringer Ingelheim
• Janssen
• Merck
• Celgene

Her academic and clinical background includes fellowship training in Clinical Dermatology Research at Baylor University Medical Center under internationally recognized psoriasis expert Dr. Alan Menter.

This expanded dermatology infrastructure allows RMP to support:
• biologic and immunology protocols
• dermatology biospecimen collection
• long-term extension studies
• inflammatory disease registries
• dermatology imaging and lesion documentation
• sponsor-driven dermatology feasibility initiatives
• multicenter dermatology recruitment programs

Gastroenterology Procedural & Biospecimen Capabilities

RMP affiliated gastroenterology investigators and centers provide procedural capabilities supporting gastrointestinal and hepatology research programs, including:

• endoscopy
• colonoscopy
• tissue biopsy collection
• gastrointestinal biospecimen procurement
• protocol-driven sample processing
• liver disease assessments
• inflammatory bowel disease evaluations
• NASH/MASH-related programs

These capabilities allow support for:
• translational research
• biomarker-driven protocols
• longitudinal GI registries
• hepatology studies
• sponsor-required tissue collection initiatives

Pulmonology & Respiratory Sample Collection Infrastructure

RMP pulmonology-affiliated investigators support respiratory and pulmonary clinical research programs through access to:
• pulmonary function testing
• respiratory disease evaluations
• protocol-specific respiratory assessments
• bronchoscopy-associated workflows
• respiratory biospecimen collection
• longitudinal pulmonary monitoring

This infrastructure supports respiratory-focused sponsors requiring coordinated pulmonary sample collection and specialized respiratory clinical oversight.

Independent Psychiatric Rater Network

RMP has established a network of independent psychiatric raters composed of psychiatry-specialized APRNs and experienced behavioral health professionals supporting CNS and psychiatry clinical trials.

This rater infrastructure supports:
• protocol-required psychiatric assessments
• standardized behavioral evaluations
• depression and anxiety rating scales
• schizophrenia-related assessments
• cognitive evaluations
• sponsor-required psychiatric scoring consistency
• centralized CNS trial support

RMP affiliated raters have experience supporting studies utilizing instruments such as:
• HAM-D
• HAM-A
• MADRS
• PANSS
• MMSE
• ADAS-COG
• C-SSRS
• DIAMOND assessments

Global Health & International Research Collaboration

RMP has established strategic international relationships and collaborative discussions involving institutions, universities, hospital systems, and healthcare stakeholders in emerging regions and developing countries.

These initiatives are focused on:
• clinical research infrastructure development
• workforce training
• operational readiness
• ethical research support
• institutional collaboration
• sustainable research ecosystem expansion

RMP is also engaged in ongoing collaborative discussions connected to global health initiatives and institutional stakeholders associated with the World Health Organization regarding support for research capacity development in underserved and emerging regions.

Additionally, RMP has established affiliations and collaborative relationships with universities and government-affiliated hospital centers in multiple countries, further expanding its operational and institutional reach across international research environments.

Medical Device Clinical Research Capabilities

RMP supports the operational implementation of medical device clinical trials across multiple therapeutic areas.

Capabilities include:
• device study startup support
• protocol implementation
• procedural coordination
• investigator training support
• device accountability workflows
• longitudinal device follow-up
• safety monitoring
• imaging integration
• sponsor/CRO coordination for device-related studies

RMP infrastructure supports both observational and interventional device programs, including studies requiring coordinated procedural workflows, imaging endpoints, and specialized operational oversight.

Sponsor & Industry Collaboration

Our investigators have conducted research in collaboration with leading pharmaceutical and biotechnology sponsors, including:
• AbbVie
• GSK
• Pfizer
• Novartis
• Sanofi
• Eli Lilly
• UCB
• Biogen
• Regeneron
• Janssen
• Merck
• Boehringer Ingelheim
• and other global research organizations

All investigators operate within RMP’s centralized operational infrastructure, integrating:
• SOP-driven execution aligned with ICH-GCP and ALCOA principles
• centralized regulatory and study start-up coordination
• real-time oversight across sites
• advanced CTMS and eSource platforms

This model ensures standardized execution, minimizes variability, and consistently delivers audit-ready, high-quality data.

Operational Model Advantage

By combining:
• experienced investigators
• embedded clinical site access
• integrated laboratory infrastructure
• imaging capabilities
• procedural workflows
• biospecimen collection capabilities
• psychiatric rater support
• and international operational collaboration

RMP provides sponsors and CROs with a fully coordinated research environment designed to reduce operational risk and optimize study outcomes across multi-site programs.

 

Representative Clinical Trial Experience

 

Oncology & Hematology

• Phase I/III study in solid tumors evaluating targeted therapies
• multicenter oncology trial in metastatic disease (treatment and progression monitoring)
• biomarker-driven oncology study involving tissue and blood-based sample collection
• oncology study integrating imaging endpoints for tumor response assessment (RECIST-based)
• Phase II study in hematologic malignancies evaluating novel therapeutic agents
• support for oncology screening and early detection programs
• longitudinal oncology registry evaluating treatment outcomes and survival
• precision medicine oncology study incorporating genomic and molecular profiling
• oncology biospecimen collection program supporting drug development and translational research
• imaging-integrated oncology study for disease monitoring and treatment response

 

Oncology Imaging & Radiation-Linked Research (Dr. Castaneda Integration)

• radiation oncology-associated studies evaluating treatment response and imaging correlation
• imaging-based oncology follow-up studies supporting longitudinal disease assessment
• integration of CT, MRI, and PET imaging in oncology protocols
• radiologic evaluation supporting clinical trial endpoints and safety monitoring
• oncology studies requiring coordination between clinical care, imaging, and data collection

 

Psychiatry & CNS Disorders

• Phase III study in Major Depressive Disorder (MDD)
• randomized study in Bipolar I Disorder (depressive episodes)
• Phase II study of a novel antipsychotic for schizophrenia
• treatment-resistant depression clinical trial
• Phase II–III study in agitation associated with Alzheimer’s disease
• multicenter study in early Alzheimer’s disease
• Phase IV maintenance study in bipolar disorder
• adjunctive therapy study for negative symptoms of schizophrenia
• relapse prevention study in major depressive disorder

Pulmonology & Respiratory Diseases

• Phase III study in Chronic Obstructive Pulmonary Disease (COPD)
• study of roflumilast add-on therapy in COPD
• randomized study in idiopathic pulmonary fibrosis (IPF)
• multicenter study in asthma control and biologic therapy
• pediatric asthma safety and efficacy trial
• inhaled nitric oxide study in pulmonary hypertension associated with COPD

Gastroenterology & Hepatology

• Phase III study in Crohn’s disease (maintenance therapy)
• Phase III study in ulcerative colitis
• Phase III study in non-alcoholic steatohepatitis (NASH)
• Phase II study in irritable bowel syndrome with constipation (IBS-C)
• hepatology study in liver fibrosis
• multicenter study in Clostridium difficile vaccine prevention

Dermatology & Immunology

• psoriasis biologic therapy studies
• atopic dermatitis clinical trials
• chronic inflammatory skin disease protocols
• hidradenitis suppurativa research programs
• long-term biologic extension studies
• dermatology immunology protocols
• plaque psoriasis multicenter studies
• dermatology biospecimen collection programs

Cardiology & Metabolic Diseases

• randomized study of sacubitril-valsartan in heart failure
• Phase III study in heart failure with iron deficiency
• cardiovascular safety study of celecoxib vs NSAIDs
• hypercholesterolemia multicenter clinical trial
• hypertension therapy conversion study
• cardiovascular outcomes study in rheumatology populations

Endocrinology & Metabolic Disorders

• randomized study in Type 2 Diabetes Mellitus
• insulin therapy comparative study in Type 1 Diabetes
• clinical trial in obesity and metabolic disorders
• Phase II study in chronic kidney disease-related anemia
• study in hyperuricemia and gout

Neurology & Pain

• Phase II study in chronic migraine treatment
• randomized trial in diabetic peripheral neuropathy pain
• post-herpetic neuralgia treatment study
• randomized study in chronic low back pain
• acute migraine treatment study (microneedle delivery system)

Rheumatology & Immunology

• Phase III study in rheumatoid arthritis
• study in psoriatic arthritis
• study in plaque psoriasis
• comparative study of biologic therapies

Infectious Diseases & Vaccines

• Phase III study in COVID-19 treatment
• CMV vaccine study
• influenza vaccine immunogenicity study
• HIV treatment optimization study

Additional Research Programs

• osteoporosis treatment study in postmenopausal women
• dermatology study in tinea pedis
• chronic urticaria and dermatology immunology trials
• pharmacogenomic registry studies
• long-term safety extension studies

​

Expanded Biospecimen, Laboratory & Imaging Infrastructure

RMP supports biospecimen-driven clinical research programs through an integrated network of CLIA-certified laboratory partners across Florida capable of supporting sample collection, processing, storage, and protocol-specific laboratory workflows.

This infrastructure includes:
• multiple CLIA-certified laboratory environments
• biospecimen collection and processing capabilities
• refrigerated and controlled sample storage
• biomarker-driven protocol support
• blood and tissue sample coordination
• translational research support
• longitudinal biospecimen management

RMP also maintains access to imaging infrastructure capable of supporting protocol-required imaging procedures and longitudinal disease assessment, including:
• CT imaging
• MRI imaging
• PET imaging
• radiologic protocol coordination
• imaging endpoint support
• disease monitoring workflows

In addition, RMP supports sleep medicine and sleep-related clinical research programs through access to a certified mobile sleep laboratory infrastructure capable of supporting:
• sleep disorder evaluations
• sleep apnea studies
• protocol-driven sleep assessments
• portable sleep monitoring
• sleep-related device studies
• longitudinal sleep data collection

This integrated infrastructure allows RMP to support sponsors and CROs requiring coordinated laboratory, biospecimen, imaging, and sleep medicine operational capabilities across multi-site clinical research programs.

                                                 Closing Statement

Through this expanded infrastructure and depth of experience, RMP offers sponsors and CROs access to a research network that goes beyond traditional site models.

We deliver integrated clinical, laboratory, imaging, procedural, biospecimen, and operational execution, enabling faster activation timelines, reliable enrollment, and consistent, high-quality study performance across a scalable multi-site research network.